Conatus Pharmaceuticals (NASDAQ: CNAT) resumed trading and is up 9.8% after announcing that the three-month ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Momentum Movers Trader Talk Trading Halts

Roth Capital Reiterates Buy Following Conatus Pharmaceuticals (CNAT) Phase II Emricasan Data January 6, 2016 9:26 AM Conatus Pharmaceuticals (CNAT) to Resume Trading at 4.35 PM ETJanuary 5, 2016 4:11 PM Conatus Pharmaceuticals (CNAT) Emricasan Phase 2 Liver Cirrhosis Trial Shows Statistically Significant Reduction in cCK18January 5, 2016 4:07 PM Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical TrialJanuary 5, 2016 4:05 PM Conatus Pharmaceuticals (CNAT) halted, news pendingJanuary 5, 2016 4:01 PM